TIDMLSIC

RNS Number : 4251P

Lifeline Scientific, Inc

05 June 2015

Lifeline Scientific

("Lifeline" or the "Company")

Posting of Annual Report & Notice of AGM

Lifeline Scientific (AIM: LSIC), the transplantation technology company, confirms that the Annual Report and Accounts for the year ended 31 December 2014 ("2014 Annual Report and Accounts"), the Notice of the Annual General Meeting ("AGM") and a Form of Proxy were posted to shareholders on 28 May 2015.

The AGM is to be held at 8:30 am US CDT on 25 June 2015 at the Westin Hotel, 400 Park Boulevard, Itasca, IL 60143, USA.

A copy of the 2014 Annual Report and Accounts is available on the Company's website: www.lifeline-scientific.com

For further information:

 
 Lifeline Scientific, Inc.                              www.lifeline-scientific.com 
 David Kravitz, CEO                                            Tel: +1 847 294 0300 
 Lisa Kieres, CFO                                              Tel: +1 847 294 0300 
 
 Panmure Gordon (UK) Limited                               Tel: +44 (0)20 7886 2500 
 Freddy Crossley (Corporate 
  Finance) 
 Maisie Atkinson (Corporate 
  Broking) 
 
 Walbrook PR Limited           Tel: +44 (0) 20 7933 8780 or lifeline@walbrookpr.com 
 Paul McManus                                              Mob: +44 (0)7980 541 893 
 Mike Wort                                                 Mob: +44 (0)7900 608 002 
 

About Lifeline Scientific Inc.

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with regional offices in Brussels and Sao Paulo. The Company's focus is the development of innovative products that improve transplant outcomes and lower the overall costs of transplantation. Its lead product, LifePort Kidney Transporter, is the global market-leading medical device for hypothermic machine preservation (HMP), of donor kidneys. LifePorts and novel solutions designed for preservation of other organs are in development, with LifePort Liver Transporter next in line for commercial launch. For more information please visit www.lifeline-scientific.com

About LifePort Kidney Transporter

Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is a proprietary medical device designed to help improve kidney preservation, evaluation and transport prior to transplantation. It has been widely studied in clinical trials throughout the world and is the standard of care for machine preservation of kidneys. Employed by surgeons in over 190 leading transplant programmes in 28 countries, LifePorts have successfully preserved over 55,000 kidneys indicated for clinical transplant. For more information please visit www.organ-recovery.com

About LifePort Liver Transporter

LifePort Liver Transporter is modelled upon the clinically proven technology platform of LifePort Kidney Transporter. The Company's early liver HMP prototype was successfully used under a US FDA Investigational Device Exemption in clinical transplant studies by surgeons at New York-Presbyterian Hospital/Columbia University Medical Center. LifePort Liver Transporter and the Company's proprietary machine preservation solution, Vasosol(R), are in the process of US and European regulatory registrations. The system is designed to help improve outcomes in liver transplantation by enabling the clinical use of hypothermic machine perfusion, and has been developed in consultation with clinical and research teams specializing in liver transplantation at Columbia University Medical Center and the University of Chicago. The system employs a rugged, streamlined ergonomic design for ease of use and transportability from donor bedside to recipient operating room. For more information please visit: http://www.organ-recovery.com/pipeline.php

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEALKSELSSEFF

Lifeline Sci (LSE:LSIC)
過去 株価チャート
から 6 2024 まで 7 2024 Lifeline Sciのチャートをもっと見るにはこちらをクリック
Lifeline Sci (LSE:LSIC)
過去 株価チャート
から 7 2023 まで 7 2024 Lifeline Sciのチャートをもっと見るにはこちらをクリック